FY2025 EPS Estimates for Eyenovia Increased by HC Wainwright

Eyenovia, Inc. (NASDAQ:EYEN) – Equities research analysts at HC Wainwright raised their FY2025 earnings per share estimates for Eyenovia in a report released on Thursday, February 6th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($16.15) per share for the year, up from their prior estimate of ($36.80). HC Wainwright has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($41.60) per share. HC Wainwright also issued estimates for Eyenovia’s FY2026 earnings at ($14.40) EPS, FY2027 earnings at ($10.85) EPS and FY2028 earnings at ($4.21) EPS.

Several other research firms have also issued reports on EYEN. Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th. LADENBURG THALM/SH SH restated a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th.

Eyenovia Stock Up 3.3 %

Eyenovia stock opened at $1.86 on Monday. Eyenovia has a fifty-two week low of $1.74 and a fifty-two week high of $205.60. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market cap of $2.59 million, a price-to-earnings ratio of -0.03 and a beta of 1.24. The firm has a fifty day moving average price of $6.44 and a two-hundred day moving average price of $30.74.

Eyenovia (NASDAQ:EYEN) last announced its earnings results on Tuesday, November 12th. The company reported ($8.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.40) by $1.60. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the previous year, the company earned ($14.40) earnings per share.

Hedge Funds Weigh In On Eyenovia

Hedge funds and other institutional investors have recently modified their holdings of the stock. Financial Management Network Inc. acquired a new position in Eyenovia during the third quarter worth $39,000. Nations Financial Group Inc. IA ADV boosted its stake in shares of Eyenovia by 78.6% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Eyenovia by 36.6% in the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after purchasing an additional 149,471 shares during the last quarter. Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.